Market Access Views & Analysis

Views & Analysis

Market Access

Beyond the Bill: how do we make medicines affordable without...

Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future.

Market Access

Frontiers Health limited podcast series, Pilar Fernández Hermida

FH25: Commercialising Health Tech and Deeptech, with Pilar F...

In a new episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with commercial strategy expert Pilar Fernández Hermida.

Market Access

pharmaphorum podcast Episode 141, Alice Valder Curran

Policy in focus: Trump’s Most Favoured Nations drug pricing ...

Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.

Market Access

Unlocking oncology access: What the OECD findings mean for m...

New policies are shaping the market access landscape, such as the introduction of the EU HTA for oncology medicines.

Market Access

Why impactful and scalable global Medical Information (MI) p...

A trusted MI partner ensures compliance with global and local regulations and provides consistent access to accurate medical information.

Market Access

neurotech representation of head in code

Neurotech patents in Europe: Methods, medical devices, and t...

The field of neurotechnology is rapidly evolving, bringing together advances in neuroscience, engineering, materials science, and computing.

Beyond the Bill: how do we make medicines affordable without...

FH25: Commercialising Health Tech and Deeptech, with Pilar F...

Policy in focus: Trump’s Most Favoured Nations drug pricing ...

Unlocking oncology access: What the OECD findings mean for m...

Why impactful and scalable global Medical Information (MI) p...

Neurotech patents in Europe: Methods, medical devices, and t...

NHS to offer Wegovy to a million more people in England

Using AI-driven synthetic personas to take your insights fur...

Views & Analysis

Editor's Picks